Dry hemostatic compositions and methods for their preparation

Information

  • Patent Grant
  • 8383141
  • Patent Number
    8,383,141
  • Date Filed
    Monday, July 21, 2008
    16 years ago
  • Date Issued
    Tuesday, February 26, 2013
    11 years ago
Abstract
Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
Description
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

NOT APPLICABLE


REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK

NOT APPLICABLE


BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates generally to collagen and collagen-derived compositions and methods for their preparation. In particular, the present invention relates to a method for producing a dry cross-linked gelatin or other collagen or collagen-derived composition which is capable of absorbing water at an enhanced rate.


Fusion Medical Technologies, Inc., assignee of the present application, produces a hemostatic composition under the FloSeal® trade name. The FloSeal® product is available in a package including two syringes. A first syringe is filled with granules of cross-linked bovine gelatin which are pre-hydrated with a buffer solution. The gelatin hydrogel contains about 85% (w/w) water and is in the form of a flowable hydrogel. Immediately prior to use in the operating room, thrombin in aqueous saline is mixed with the gelatin hydrogel. The thrombin is prepared in saline and drawn up in a second syringe, and the syringes are connected together permitting mixing of thrombin and the gelatin.


The resulting mixture of the gelatin hydrogel granules and the thrombin has been found to be a highly effective hemostatic sealant when applied to a bleeding site. Typically, the sealant will be applied through the syringe in which it has been mixed to the bleeding site. Blood will percolate through the resulting bed of hydrogel granules, and the thrombin reacts with fibrinogen in the blood to form a fibrin clot around the gelatin to seal the bleeding site.


Although highly effective, the present FloSeal® product has a limited shelf life. It is believed that the stability of the gelatin is reduced by hydrolysis of the packaged hydrogel. To limit possible hydrolytic degradation, the FloSeal® product is usually shipped in a temperature-protected packaging.


For these reasons, it would be desirable to provide improved hemostatic sealing compositions of the type which combine a collagen, gelatin, or other collagen-derived hydrogel with a thrombin-containing aqueous solution. In particular, it would be desirable to provide such compositions in a form which would be resistant to hydrolytic degradation and which would therefore have a longer shelf life. It would be particularly desirable to provide improved compositions having both comparable hemostatic activity to the present FloSeal® product and longer shelf lives. Such compositions would be most beneficial if they could be rapidly re-hydrated for subsequent use, typically so that they could be extruded through a syringe. At least some of these objectives will be met by the inventions described hereinafter.


2. Description of the Background Art


The FloSeal® product available from Fusion Medical Technologies, Inc., is described in Hood et al., Efficacy of Topical Hemostat FloSeal™ in Vascular Surgery, an Abstract funded by Fusion Medical Technologies, Inc., which was publicly presented in September 1999. Patents covering the FloSeal® product include U.S. Pat. Nos. 6,063,061 and 6,066,325. A dual syringe system suitable for mixing and delivering a collagen, gelatin, or other collagen-derived component and a thrombin component of the FloSeal™ product is described in U.S. Pat. No. 5,908,054. The complete disclosures of each of these patent references is hereby incorporated by reference.


BRIEF SUMMARY OF THE INVENTION

The present invention provides improved hemostatic sealing compositions, methods for preparing such improved compositions, and kits comprising the improved compositions. The methods and compositions will be particularly useful for providing hemostasis at bleeding sites, including surgical bleeding sites, traumatic bleeding sites and the like. An exemplary use of the compositions may be in sealing the tissue tract above a blood vessel penetration created for vascular catheterization.


The compositions comprise a dry cross-linked gelatin powder which has been prepared to re-hydrate rapidly. The gelatin powder preferably comprises relatively large particles, also referred to as fragments or sub-units, as described in U.S. Pat. Nos. 6,063,061 and 6,066,325, the full disclosures of which have previously been incorporated by reference. A preferred particle size will be the range from 150 μm to 750 μm, but particle sizes outside of this preferred range may find use in many circumstances. The dry compositions will also display a significant “equilibrium swell” when exposed to an aqueous re-hydrating medium. Preferably, the swell will be in the range from 400% to 1000%, but may fall outside of this range as set forth in the above-referenced patents. “Equilibrium swell” may be determined by subtracting the dry weight of the gelatin hydrogel powder from its weight when fully hydrated and thus fully swelled. The difference is then divided by the dry weight and multiplied by 100 to give the measure of swelling. The dry weight should be measured after exposure of the material to an elevated temperature for a time sufficient to remove substantially all residual moisture, e.g., two hours at 120° C. The equilibrium hydration of the material can be achieved by immersing the dry material in a suitable re-hydrating medium, such as aqueous saline, for a time period sufficient for the water content to become constant, typically for from 18 to 24 hours at room temperature.


The dry cross-linked gelatin powders of present invention will usually have some residual moisture, but will be sufficiently dry to achieve the desired stability and extended shelf life. Typically, the dry compositions will have a moisture content below 20% by weight (w/w) or less, preferably having a moisture content in the range from 5% by weight to 15% by weight. To maintain dryness, the compositions will typically be packaged in a manner suitable to prevent moisture incursion, as described in more detail in connection with the kits of the present invention.


In one particular aspect of the present invention, compositions will comprise cross-linked gelatin powders having a moisture content of 20% (w/w) or less, wherein the powder was cross-linked in the presence of a re-hydration aid so that the powder has an aqueous re-hydration rate which is at least 5% higher than the re-hydration rate of a similar powder prepared without the re-hydration aid. The “re-hydration rate” is defined herein to mean the quantity of an aqueous solution, typically 0.9% (w/w) saline, that is absorbed by a gram of the powder (dry weight basis) within thirty seconds, expressed as gm/gm. Particular techniques for measuring this rate are described in the Experimental section hereinafter. Preferred compositions of the present invention will have a re-hydration rate of at least 3 gm/gm, preferably at least 3.5 gm/gm, and often 3.75 gm/gm or higher. Re-hydration rates of similar powders prepared without the re-hydration aids are typically below three, and a percentage increase in re-hydration rate will usually be at least 5%, preferably being at least 10%, and more preferably being at least 25% or higher.


The dry cross-linked gelatin powders of the present invention having improved re-hydration rates are preferably obtained by preparing the powders in the presence of certain re-hydration aids. Such re-hydration aids will be present during the preparation of the powders, but will usually be removed from the final products. For example, re-hydration aids which are present at about 20% of the total solids content, will typically be reduced to below 1% in the final product, often below 0.5% by weight. Exemplary re-hydration aids include polyethylene glycol (PEG), preferably having a molecular weight of about 1000; polyvinylpyrrolidone (PVP), preferably having an average molecular weight of about 50,000; and dextran, typically having an average molecular weight of about 40,000. It is preferred to employ at least two of these re-hydration aids when preparing the compositions of the present invention, and more particularly preferred to employ all three.


The methods of the present invention thus comprise providing an aqueous solution of a non-cross-linked gelatin combined with a re-hydration aid. The non-cross-linked gelatin will typically be present in an aqueous solution at from 5% (w/w) to 15% (w/w) and the re-hydration aids will be typically present from 5% to 30% (w/w) based on the weight of gelatin in the aqueous solution. Preferably, the re-hydration aid comprises PEG at from 2.5% to 20% (w/w) based on the weight of the gelatin, PVP at from 1.25% to 20% (w/w), and dextran at from 1.25% to 20% (w/w).


The non-cross-linked gelatin together with the re-hydration aid is then cross-linked in any manner suitable to form the hydrogel. For example, polymeric molecules may be cross-linked using bi- or poly-functional cross-linking agents which covalently attach to two or more polymer molecules chains. Exemplary bifunctional cross-linking agents include aldehydes, epoxies, succinimides, carbodiimides, maleimides, azides, carbonates, isocyanates, divinyl sulfone, alcohols, amines, imidates, anhydrides, halides, silanes, diazoacetate, aziridines, and the like. Alternatively, cross-linking may be achieved by using oxidizers and other agents, such as periodates, which activate side-chains or moieties on the polymer so that they may react with other side-chains or moieties to form the cross-linking bonds. An additional method of cross-linking comprises exposing the polymers to radiation, such as gamma radiation, to activate the polymer chains to permit cross-linking reactions. Dehydrothermal cross-linking methods may also be suitable. Preferred methods for cross-linking gelatin molecules are described below.


Exemplary methods for producing cross-linked gelatins are as follows. Gelatin is obtained and suspended in an aqueous solution to form a non-cross-linked hydrogel, typically having a solids content from 1% to 70% by weight, usually from 3% to 10% by weight. The gelatin is cross-linked, typically by exposure to either glutaraldehyde (e.g., 0.01% to 0.05% w/w, overnight at 0 C to 15 C in aqueous buffer), sodium periodate (e.g., 0.05 M, held at 0° C. to 15° C. for 48 hours) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (“EDC”) (e.g., 0.5% to 1.5% w/w overnight at room temperature), or by exposure to about 0.3 to 3 megarads of gamma or electron beam radiation. Alternatively, gelatin particles can be suspended in an alcohol, preferably methyl alcohol or ethyl alcohol, at a solids content of 1% to 70% by weight, usually 3% to 10% by weight, and cross-linked by exposure to a cross-linking agent, typically glutaraldehyde (e.g., 0.01% to 0.1% w/w, overnight at room temperature). In the case of aldehydes, the pH should be held from about 6 to 11, preferably from 7 to 10. When cross-linking with glutaraldehyde, the cross-links are formed via Schiff bases which may be stabilized by subsequent reduction, e.g., by treatment with sodium borohydride. After cross-linking, the resulting granules may be washed in water and optionally rinsed in an alcohol, and dried. The resulting dry powders may then be loaded into the applicators of the present invention, as described in more detail hereinafter.


After cross-linking, at least 50% (w/w) of the re-hydration aid will be removed from the resulting hydrogel. Usually, the re-hydration aid is removed by filtration of the hydrogel followed by washing of the resulting filter cake. Such filtration/washing steps can be repeated one or more additional times in order to clean the product to a desired level and to remove at least 50% of the re-hydration aid, preferably removing at least 90% (w/w) of the re-hydration aid originally present.


After filtration, the gelatin is dried, typically by drying the final filter cake which was produced. The dried filter cake may then be broken up or ground to produce the cross-linked powder having a particle size in the desired ranges set forth above.


Kits according to the present invention will comprise a first container holding the dry cross-linked gelatin powder of the present invention, as described above. The kits will further comprise a second container holding an aqueous re-hydration medium, typically a saline or other aqueous solution comprising thrombin which is intended to be mixed with the gelatin as the gelatin is re-hydrated. The containers can be in any form, but will preferably be in the form of syringes which permit mixing of the dry gelatin with the re-hydration medium.





BRIEF DESCRIPTION OF THE DRAWING


FIG. 1 illustrates a kit constructed in accordance with the principles of the present invention.





DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The following examples are offered by way of illustration, not by way of limitation.


EXAMPLE 1
Preparation of Gelatin Powder

Strips of bovine corium were suspended in a sodium hydroxide solution of concentration 1 M to 2 M for 1 hr at room temperature, neutralized with phosphoric acid, and rinsed. The treated strips were then resuspended in deionized water, adjusted to pH 7-8, and heated to 70° C. A homogenizer was used to further reduce the size of the strips. After 1 hr at 70° C., the corium was largely solubilized to gelatin. The amount of corium was chosen so that the solids content of the resulting gelatin solution was approximately 3-10% (w/w), typically 7-10%. The solution was cast as thin layers onto Teflon® coated metal trays, dried, and ground to form gelatin powder.


EXAMPLE 2
Preparation of “Modified Gelatin Powder”

Re-hydration aids (Table 1) were dissolved in 500 mL of 50° C. de-ionized water and then an amount of bovine derived gelatin powder, prepared as in Example 1, was added to the solution. The final concentration of gelatin in solution was chosen to be approximately 8% (w/w, bulk gelatin powder basis), and the total amount of re-hydration aids in the solution was chosen as in Examples 9-44 (Tables 1 and 2). After the gelatin had dissolved, the solution was poured into Teflon® coated metal trays and dried. The dried gelatin sheet is ground to form “modified gelatin powder”.


Alternatively, strips of bovine corium were suspended in a sodium hydroxide solution of concentration 1 M to 2 M for 1 hr at room temperature, neutralized with phosphoric acid, and rinsed. The treated strips were then resuspended in deionized water, adjusted to pH 7-8, and heated to 70° C. A homogenizer was used to further reduce the size of the strips. After 1 hr at 70° C., the corium was largely solubilized to gelatin. The amount of corium was chosen so that the solids content of the resulting gelatin solution was approximately 3-10% (w/w), typically 7-10%. Amounts of re-hydration aids were chosen as in Examples 9-44 (Tables 1 and 2) and were then added to the gelatin solution, either in solid form or dissolved in a small volume of water. The solution was cast into thin layers onto Teflon® coated metal trays, dried, and ground to form “modified gelatin powder”. Examples of several formulations for modified gelatin are given in Tables 1 and 2.


EXAMPLE 3
Preparation of Cross-Linked Gelatin Powder from “Modified Gelatin Powder”

600 mL of 0.2 M phosphate buffer (pH 9.2±0.2) was cooled to a temperature below 12° C. 0.32 mL of glutaraldehyde (25%) was added to the buffer solution and then 20 g of modified gelatin powder was added, resulting in a glutaraldehyde concentration of 4000 ppm (glutaraldehyde to modified gelatin, bulk weight basis). The gelatin was suspended in the glutaraldehyde solution with a stir bar. The pH of each suspensions was adjusted to a range of 9.2±0.2 and then maintained at a temperature of 9 to 12° C. and pH of 9.2±0.2 over 19 hours.


The suspension was filtered and the filter cake was washed with de-ionized water three times by completely covering the filter cake with de-ionized water and then allowing the vacuum to draw the rinse water through the cake. The filter cake was left in the funnel during each rinse.


0.2 g of NaBH4 was dissolved in 600 mL 25 mM phosphate buffer, pH 7.4 0.2, in a beaker. The above filter cake was suspended in the NaBH4 solution at room temperature (about 22° C.) for 3 hours, then filtered to remove the liquid.


The filter cake was next suspended in 600 mL of buffer solution at room temperature (about 22° C.) for 30 minutes and filtered again. The buffer was composed of sodium phosphate (dibasic anhydrous and monobasic monohydrate) and sodium ascorbate. The above procedure was repeated twice to ensure that the appropriate ratio of salts to gelatin were present to form the desired buffer composition upon reconstitution. The filter cake was dried, then ground with a Waring Blender, resulting in “cross-linked gelatin powder”.


This method was also used to prepare cross-linked gelatin powder from unmodified gelatin powder; that is, gelatin to which no re-hydration aids were added during its preparation.


EXAMPLE 4
Preparation of Irradiated Product from Cross-Linked Gelatin Powder

About 800 mg (bulk weight) of the cross-linked gelatin powder, prepared as in Example 2, were put into each of several 5 cc syringes. The syringes containing powder were sterilized with gamma irradiation at ambient temperature.


EXAMPLE 5
Use of Product as a Hemostatic Agent

A syringe of product containing approximately 0.8 g of irradiated cross-linked gelatin powder was prepared from modified gelatin powder. The modified gelatin powder was prepared as in Example 2. The modified gelatin was further cross-linked and irradiated as in Examples 3 and 4. The product was mixed with 4 mL of a saline solution containing about 1000 Units of bovine thrombin per milliliter. Mixing was achieved by passage back and forth between two syringes connected with a female-female straight-through Luer connector. The powder in the syringe was hydrated as it mixed with the thrombin solution, forming granules of hydrogel.


A square lesion, approximately 1 cm×1 cm×0.2 cm deep, was created on the liver of a farm-grade pig. The pig had been anticoagulated with heparin so that its activated clotting time (ACT) was three to five times its baseline value, and the lesion bled freely prior to treatment. After about 30 seconds from the start of mixing, approximately 2 mL of the hydrated powder was extruded from the syringe onto the lesion and held in place with compression for two minutes. After compression was removed, the treated lesion was observed for bleeding at 3 min, 10 min, and 50 min after application. No bleeding was seen from the treated lesion at the 3 min and 10 min observation. After the 10 min observation, the treated lesion was irrigated with saline solution. While excess material was removed, no re-bleeding was observed. At 50 min after application, the lesion was observed again and no bleeding was seen.


EXAMPLE 6
Determination of Re-Hydration Rate of a Powder

The “re-hydration rate” of a powder was measured as follows. The powder, packed in a 5 cc syringe, was mixed with a syringe containing a volume of aqueous solution by passage between the two syringes connected with a Luer fitting for 30 seconds. The volume of aqueous solution was chosen to be in excess of what could be expected to be absorbed in 30 seconds. Typically, 0.8 g (bulk weight) of powder was mixed with 3 mL of 0.9% sodium chloride solution. The resulting mixture was then immediately filtered to remove any unabsorbed liquid. The wet filtered material was weighed, then dried in a 120° C. oven for two hours and re-weighed. This measurement gave the total amount of water removed from the wet material and the weight of the dry powder. The amount of water that had been absorbed by the powder was then calculated after a small correction is made for the residual moisture that had been present in the powder originally. The “re-hydration rate” was given as the mass of saline solution absorbed per gram dry weight of powder in that 30 second interval.


In the calculation below, the fraction solids of the bulk powder (“S”) was measured independently by drying the bulk powder at 120° C. for 2 hr and weighing the powder before and after drying. The value of S is given by the following:






S
=



weight











after





drying





at





120

°






C
.


,

2





hr



weight





before





drying








    • Re-hydration rate calculation:

    • A: initial weight of the pan and filter paper

    • B: weight of the pan, filter paper and hydrated powder

    • C: weight of the pan, filter paper and sample after drying in oven

    • S: fraction solids of the bulk powder originally in syringe

    • M: grams of saline absorbed per gram of powder (dry weight) during mixing (“absorption rate”)









M
=



(

B
-
A

)

-


(

C
-
A

)

/
S



(

C
-
A

)






EXAMPLE 7
Re-Hydration Rate and Physical Property Determination for Several Batches of Powder Product

Tables 1 and 2 depict the results of re-hydration rate measurements performed on one to for several batches of powder product (Examples 9-23). These were made using methods as per Examples 1, 2, 3, and 4. Except for Examples 9 and 17, these were prepared from modified gelatins that were made with various proportions of gelatin and the following re-hydration aids: polyethylene glycol (PEG), average molecular weight 1000; polyvinylpyrrolidone (PVP), “k-30” designation, corresponding to an average molecular weight of about 50,000; and dextran, average molecular weight 40,000.


It is seen that use of several different combinations of gelatin and re-hydration aids can result in a powder product that absorbs more aqueous saline solution in 30 seconds per gram of powder than powder product made from gelatin to which no re-hydration aids have been added. It is also seen that the combination of gelatin, PEG, PVP and dextran at a bulk weight ratio of 80:10:5:5 in the modified gelatin (Example 10) produces a powder product that absorbs about 33% more saline solution per gram in 30 seconds than powder product made from unmodified gelatin.


Table 1 also gives values for other physical properties determined for the powder product lots. “Percent solids” was determined by weighing the powder before and after drying at 120° C. for two hours to drive off residual moisture. “DSC peak temperature” refers to the temperature at which a peak is exhibited in a thermogram of a differential scanning calorimetry measurement conducted from 1° C. to 70° C. “Equilibrium swell” was determined by suspending the powder in an excess of saline solution for at least 18 hr at room temperature. The hydrated powder was weighed to determine its “equilibrium wet weight” and dried at 120° C. for two hours and re-weighed to determine its “dry weight”. Equilibrium swell is given as







Equilibrium





swell






(
%
)


=

100

%
×



equilibrium











wet





weight

-

dry





weight



dry





weight







Values for “mean particle size” were measured by light scattering in a Coulter LS particle size analyzer.


From the data presented in Table 1, it appears that the appropriate use of re-hydration aids can change the re-hydration rate of the powder product without significantly changing other physical properties.


EXAMPLE 8
Measurement of Polyethylene Glycol, Polyvinylpyrrolidone, and Dextran Levels in Modified Gelatin Powder and in Cross-Linked Powder

Approximately 50 mg modified gelatin or 250 mg cross-linked irradiated powder product were suspended in 10 mL of deionized water and heated for 3 hr at 65° C. The samples were then centrifuged at 15 minutes at 2000 rpm. The resulting supernatant was filtered through a 0.45 μm Gelman Acrodisc filter, the first mL being discarded. The resulting sample was then assayed by three different high performance liquid chromatography (HPLC) methods to quantitate the polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), and dextran in the sample. For PEG, 100 μL of the sample was injected onto a Waters Ultrahydrogel 120 column, 7.8×300 mm, with guard column and prefilter, using deionized water as the mobile phase. A refractive index detector was used to monitor the effluent. For PVP, 100 μL of the sample was injected onto a Phenomenex Kingsorb C18 5 μm column, 4.6×150 mm, with guard column and prefilter, using a gradient of methanol and aqueous sodium phosphate as the mobile phase. An ultraviolet absorbance detector was used to monitor the effluent. For dextran, 100 μL of the sample was injected onto a Waters Ultrahydrogel Linear column, 7.8×300 mm, with guard column and prefilter, using 0.1 M sodium phosphate, pH 7 and acetonitrile at a 90:10 ratio as the mobile phase. A refractive index detector was used to monitor the effluent. All columns were heated to 40° C. for the analyses. The limit of quantitation was about 0.1% (w/w sample) for PEG and PVP, 0.2% (w/w sample) for dextran.


Modified gelatin was prepared as per Example 2. The modified gelatin was analyzed for PEG, PVP and dextran in the manner described above. Results indicated that PEG, PVP, and dextran were present at 16%, 8%, and 3% (w/w bulk) respectively. The modified gelatin was subsequently subjected to cross-linking, sodium borohydride treatment, and rinsing as per Example 3 to form cross-linked modified gelatin powder. When this powder was analyzed for PEG, PVP, and dextran by HPLC in the manner described above, the content of each of the three re-hydration aids was found to be below the limit of quantitation.


EXAMPLE 9
Powder Product Made without Re-Hydration Aids

Unmodified gelatin—that is, gelatin to which processing aids were not added—was prepared from bovine corium strips as in Example 1 and cross-linked as in Example 3. The cross-linked unmodified gelatin was then packed into syringes and gamma irradiated as in Example 4. Physical properties of the resulting product were measured as in Examples 6 and 7 and are given in Table 1.


EXAMPLES 10-23
Powder Product Made with Re-Hydration Aids

Batches of modified gelatin were prepared as in Example 2 from gelatin powder or corium strips and from one, two, or three re-hydration aids. Table 1 gives the proportions of bulk gelatin and re-hydration aids used. The modified gelatin was then cross-linked as in Example 3. Except for Example 17, the re-hydration aids used were from the following list: polyethylene glycol (PEG) of an average molecular weight of about 1000; polyvinylpyrrolidone (PVP), “k-30” designation, of an average molecular weight of about 50,000; and dextran, of an average molecular weight of about 40,000. In Example 17, PEG of an average molecular weight of about 400 was used. The cross-linked modified gelatin was then packed into syringes and gamma irradiated as in Example 4. Physical properties of the resulting powder product from each of these preparations were measured as in Examples 6 and 7 and are given in Table 1. Data given with the formulation for Example 10 is the average and standard deviation of nine batches prepared according to that formulation.


Examples 24-44
Powder Product Made with Various Re-Hydration Aids

Batches of modified gelatin were prepared as in Example 2 from gelatin powder or corium strips and from one of several re-hydration aids. Table 2 gives the identity and concentration of re-hydration aid used in each batch as a ratio of bulk gelatin weight to re-hydration aid and as a percentage of total bulk solute used to prepare the modified gelatin. The modified gelatin was then cross-linked as in Example 3. The cross-linked modified gelatin was then packed into syringes and gamma irradiated as in Example 4. Physical properties of the resulting powder product from each of these preparations were measured as in Examples 6 and 7 and are given in Table 2. Data for the Example 9 formulation is provided in Table 2 for comparison.












TABLE 1










Properties of powder product after



Target bulk weight percent in
cross-linking and gamma irradiation



modified gelatin
(re-hydration aids largely removed)



















Gelatin
PEG
PVP
Dextran

DSC

Mean





(bulk
MW =
MW~
MW =
%
peak temp
Equilibrium
particle
Re-



Lot
weight)
1000 D
50000 D
40000 D
solids
(° C)
swell (%)
size (μm)
hydration*





















No re-hydration












aids added


Example 9
208-32
100
 0
0
0
88.6
41.3
551
440
2.85


Preferred


composition


(four-way mixture)


Example 10
avg of 9 lots
80
10
5
5
87.6
42.1
595
423
3.79



std. deviation




1.0
1.4
43
65
0.15



of 9 lots


Three-way


mixtures


Example 11
228-69-1
80
10
10
0
88.1
40.8
667
387
3.51


Example 12
228-69-2
80
10
0
10
88.4
40.6
670
367
3.14


Example 13
228-78
80
 0
10
10
86.7
41.1
632
414
3.20


Gelatin-PEG


mixtures


Example 14
212-39-2
94
 6
0
0
86.2
44.4
502
372
2.68


Example 15
228-42-3
89
11
0
0
88.6
42.8
594
428
3.16


Example 16
228-42-1
80
20
0
0
88.9
42.4
575
312
3.47


Example 17
214-62-1
89
11**
0
0
87.1
40.7
599
406
3.11


Gelatin-PVP


mixtures


Example 18
228-38-3
94
 0
6
0
88.2
42.2
567
399
3.26


Example 19
228-38-2
89
 0
11
0
88.3
41.0
605
422
3.44


Example 20
228-38-1
80
 0
20
0
88.6
42.4
596
401
3.52


Gelatin-dextran


mixtures


Example 21
228-35-3
94
 0
0
6
88.1
40.5
631
395
3.18


Example 22
228-35-2
89
 0
0
11
88.3
41.4
598
345
3.03


Example 23
228-35-1
80
 0
0
20
88.5
41.9
624
392
3.01





*Re-hydration rate defined as grams saline absorbed per gram powder product (dry wt) in 30 sec


**PEG (MW = 400) used instead of MW = 1000
















TABLE 2









Re-hydration aid











Conc'n of




processing
Physical properties






















aid in

DSC








MW or
bulk
modified

peak

Mean
Re-





other
gelatin
gelatin
%
temp
Equilibrium
particle
hydration



Lot
type
designation
wt: aid
(bulk wt %)
solids
(° C.)
swell (%)
size (μm)
rate*


















Example 9
208-32
no re-hydration aids
88.6
41.3
551
440
2.85

















Example 24
214-11-1
glycerol
n/a
4
20%
85.5
43.4
483
653
2.19


Example 25
214-11-2
glycerol
n/a
8
11%
86.4
43.4
529
421
2.62


Example 26
214-11-3
glycerol
n/a
16
 6%
86.5
43.0
543
398
2.35


Example 27
214-44-1
dextran
148000 D
4
20%
85.5
nr
634
433
2.62


Example 28
214-44-2
dextran
148000 D
8
11%
85.4
nr
607
453
2.57


Example 29
214-44-3
dextran
148000 D
16
 6%
85.5
nr
603
527
2.33


Example 30
214-44-4
dextran
148000 D
32
 3%
85.7
nr
531
491
2.37


Example 31
228-35-4
dextran
 40000 D
32
 3%
84.5
41.4
633
380
2.59


Example 32
214-50-1
PVP
k-90
4
20%
85.3
44.0
612
664
2.41


Example 33
214-50-2
PVP
k-90
8
11%
85.6
44.3
538
581
2.71


Example 34
214-50-3
PVP
k-90
16
 6%
85.6
44.1
527
593
2.78


Example 35
214-50-4
PVP
k-90
32
 3%
86.1
43.0
597
538
2.76


Example 36
214-53-4
PVP
k-30
32
 3%
87.3
41.1
580
447
2.72


Example 37
214-59-1
PEG
 400
4
20%
86.7
42.0
595
407
2.18


Example 38
214-66-1
PEG
 400
6
14%
86.5
40.8
603
501
2.63


Example 39
212-39-1
PEG
 400
16
 6%
86.2
43.8
513
403
2.11


Example 40
212-39-2
PEG
1000
16
 6%
86.2
44.4
502
372
2.68


Example 41
214-59-3
PEG
8000
4
20%
87.4
41.5
548
429
2.87


Example 42
214-66-3
PEG
8000
6
14%
86.9
41.4
581
426
3.80


Example 43
214-62-3
PEG
8000
8
11%
86.8
42.0
631
511
2.78


Example 44
212-39-3
PEG
8000
16
 6%
86.4
44.6
546
518
2.72





nr = not reported


*Re-hydration rate defined as grams saline absorbed per gram powder product (dry wt) in 30 sec






While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.

Claims
  • 1. A composition comprising cross-linked gelatin powder having a moisture content of 20% (w/w) or less and a re-hydration rate of at least 3 gm/gm in 30 seconds, wherein the composition further comprises a re-hydration aid, the re-hydration aid selected from the group consisting of: polyethylene glycol (PEG) having an average molecular weight of about 1000, polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000, and dextran having an average molecular weight of about 40,000;polyethylene glycol (PEG) having an average molecular weight of about 1000 and polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000;polyethylene glycol (PEG) having an average molecular weight of about 1000 and dextran having an average molecular weight of about 40,000;polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000 and dextran having an average molecular weight of about 40,000;polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000; anddextran having an average molecular weight of about 40,000.
  • 2. A composition as in claim 1, wherein the powder has a mean particle size in the range from 150 μm to 750 μm.
  • 3. A composition as in claim 2, wherein the powder has an equilibrium swell in the range from 400% to 1000%.
  • 4. A composition as in claim 1, wherein the powder has a moisture content in the range from 5% (w/w) to 15% (w/w).
  • 5. A composition comprising cross-linked gelatin powder having a moisture content of 20% (w/w) or less and a re-hydration rate of at least 3 gm/gm in 30 seconds, wherein the composition further comprises a re-hydration aid, the re-hydration aid selected from the group consisting of: polyethylene glycol (PEG) having an average molecular weight of about 1000, polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000, and dextran having an average molecular weight of about 40,000;polyethylene glycol (PEG) having an average molecular weight of about 1000 and polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000;polyethylene glycol (PEG) having an average molecular weight of about 1000 and dextran having an average molecular weight of about 40,000;polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000 and dextran having an average molecular weight of about 40,000;polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000; anddextran having an average molecular weight of about 40,000 andwherein the powder has a mean particle size in the range from 150 μm to 750 μm, and wherein the powder has an equilibrium swell in the range from 400% to 1000%.
  • 6. A composition as in claim 5, wherein the powder has a moisture content in the range from 5% (w/w) to 15% (w/w).
  • 7. A composition as in claim 1, wherein the re-hydration aid is polyethylene glycol (PEG) having an average molecular weight of about 1000, polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000, and dextran having an average molecular weight of about 40,000.
  • 8. A composition as in claim 1, wherein the re-hydration aid is polyethylene glycol (PEG) having an average molecular weight of about 1000 and polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000.
  • 9. A composition as in claim 1, wherein the re-hydration aid is polyethylene glycol (PEG) having an average molecular weight of about 1000 and dextran having an average molecular weight of about 40,000.
  • 10. A composition as in claim 1, wherein the re-hydration aid is polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000 and dextran having an average molecular weight of about 40,000.
  • 11. A composition as in claim 1, wherein the re-hydration aid is polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000.
  • 12. A composition as in claim 1, wherein the re-hydration aid is dextran having an average molecular weight of about 40,000.
  • 13. A composition as in claim 1, wherein the re-hydration rate is between 3 and 3.79 gm/gm in 30 seconds.
  • 14. A composition as in claim 1, wherein the re-hydration aid is present at below 0.1% of the composition.
  • 15. A composition as in claim 5, wherein the re-hydration aid is polyethylene glycol (PEG) having an average molecular weight of about 1000, polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000, and dextran having an average molecular weight of about 40,000.
  • 16. A composition as in claim 5, wherein the re-hydration aid is polyethylene glycol (PEG) having an average molecular weight of about 1000 and polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000.
  • 17. A composition as in claim 5, wherein the re-hydration aid is polyethylene glycol (PEG) having an average molecular weight of about 1000 and dextran having an average molecular weight of about 40,000.
  • 18. A composition as in claim 5, wherein the re-hydration aid is polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000 and dextran having an average molecular weight of about 40,000.
  • 19. A composition as in claim 5, wherein the re-hydration aid is polyvinylpyrrolidone (PVP) having an average molecular weight of about 50,000.
  • 20. A composition as in claim 5, wherein the re-hydration aid is dextran having an average molecular weight of about 40,000.
  • 21. A composition as in claim 5, wherein the re-hydration rate is between 3 and 3.79 gm/gm in 30 seconds.
  • 22. A composition as in claim 5, wherein the re-hydration aid is present at below 0.1% of the composition.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 09/908,464, entitled “DRY HEMOSTATIC COMPOSITIONS AND METHODS FOR THEIR PREPARATION,” filed Jul. 17, 2001, the entire disclosures of which are incorporated herein by reference for all purposes.

US Referenced Citations (136)
Number Name Date Kind
2507244 Correll May 1950 A
2558395 Studer Jun 1951 A
3089315 Kupelwieser et al. May 1963 A
4006220 Gottlieb Feb 1977 A
4013078 Field Mar 1977 A
4124705 Rothman et al. Nov 1978 A
4164559 Miyata et al. Aug 1979 A
4179400 Tsao et al. Dec 1979 A
4265233 Sugitachi et al. May 1981 A
4291013 Wahlig et al. Sep 1981 A
4292972 Pawelchak et al. Oct 1981 A
4298598 Schwarz et al. Nov 1981 A
4300494 Graiff et al. Nov 1981 A
4347234 Wahlig et al. Aug 1982 A
4362567 Schwarz et al. Dec 1982 A
4377572 Schwarz et al. Mar 1983 A
4424208 Wallace et al. Jan 1984 A
4453939 Zimmerman et al. Jun 1984 A
4482386 Wittwer et al. Nov 1984 A
4515637 Cioca May 1985 A
4536387 Sakamoto et al. Aug 1985 A
4540410 Wood et al. Sep 1985 A
4543332 Jao et al. Sep 1985 A
4554156 Fischer Nov 1985 A
4600574 Lindner et al. Jul 1986 A
4640834 Eibl et al. Feb 1987 A
4655211 Sakamoto et al. Apr 1987 A
4746514 Warne May 1988 A
4749689 Miyata et al. Jun 1988 A
4803075 Wallace et al. Feb 1989 A
4818517 Kwee et al. Apr 1989 A
4832686 Anderson May 1989 A
4837285 Berg et al. Jun 1989 A
4885161 Cornell Dec 1989 A
4891359 Saferstein et al. Jan 1990 A
4925677 Feijen May 1990 A
4946870 Partain, III. et al. Aug 1990 A
5007916 Linsky et al. Apr 1991 A
5017229 Burns et al. May 1991 A
5023082 Friedman et al. Jun 1991 A
5041292 Feijen Aug 1991 A
5061274 Kensey Oct 1991 A
5061492 Okada et al. Oct 1991 A
5080893 Goldberg et al. Jan 1992 A
5108421 Fowler Apr 1992 A
5126141 Henry Jun 1992 A
5129882 Weldon et al. Jul 1992 A
5134229 Saferstein et al. Jul 1992 A
5135751 Henry et al. Aug 1992 A
5135755 Czech et al. Aug 1992 A
5140016 Goldberg et al. Aug 1992 A
5149540 Kunihiro Sep 1992 A
5162430 Rhee et al. Nov 1992 A
5165938 Knighton Nov 1992 A
5178883 Knighton Jan 1993 A
5192300 Fowler Mar 1993 A
5196185 Silver et al. Mar 1993 A
5204382 Wallace et al. Apr 1993 A
5209776 Bass et al. May 1993 A
5219328 Morse et al. Jun 1993 A
5275616 Fowler Jan 1994 A
5292362 Bass et al. Mar 1994 A
5300494 Brode, II et al. Apr 1994 A
5304377 Yamada et al. Apr 1994 A
5306501 Viegas et al. Apr 1994 A
5324775 Rhee et al. Jun 1994 A
5328955 Rhee et al. Jul 1994 A
5330446 Weldon et al. Jul 1994 A
5350573 Goldberg et al. Sep 1994 A
5352715 Wallace et al. Oct 1994 A
5356614 Sharma Oct 1994 A
5384333 Davis et al. Jan 1995 A
5385606 Kowanko Jan 1995 A
5399361 Song et al. Mar 1995 A
5418222 Song et al. May 1995 A
5428022 Palefsky et al. Jun 1995 A
5428024 Chu et al. Jun 1995 A
5437672 Allyne Aug 1995 A
5447966 Hermes et al. Sep 1995 A
5478352 Fowler Dec 1995 A
5507744 Tay et al. Apr 1996 A
5510418 Rhee et al. Apr 1996 A
5512301 Song et al. Apr 1996 A
5514379 Weissleder et al. May 1996 A
5516532 Atala et al. May 1996 A
5520925 Maser May 1996 A
5531759 Kensey et al. Jul 1996 A
5540715 Katsaros et al. Jul 1996 A
5580923 Yeung et al. Dec 1996 A
5595735 Saferstein et al. Jan 1997 A
5614587 Rhee et al. Mar 1997 A
5618551 Tardy et al. Apr 1997 A
5648506 Desai et al. Jul 1997 A
5658592 Tanihara et al. Aug 1997 A
5667839 Berg Sep 1997 A
5672336 Sharma Sep 1997 A
5674275 Tang et al. Oct 1997 A
5690675 Sawyer et al. Nov 1997 A
5698213 Jamiolkowski et al. Dec 1997 A
5714370 Eibl et al. Feb 1998 A
5752974 Rhee et al. May 1998 A
5770229 Tanihara et al. Jun 1998 A
5853749 Hobbs Dec 1998 A
5874500 Rhee et al. Feb 1999 A
5902832 Van Bladel et al. May 1999 A
5908054 Safabash et al. Jun 1999 A
5931165 Reich et al. Aug 1999 A
5997895 Narotam et al. Dec 1999 A
6063061 Wallace et al. May 2000 A
6066325 Wallace et al. May 2000 A
6110484 Sierra Aug 2000 A
6129761 Hubbell Oct 2000 A
6166130 Rhee et al. Dec 2000 A
6179872 Bell et al. Jan 2001 B1
6227394 Sierra Aug 2001 B1
6312474 Francis et al. Nov 2001 B1
6312725 Wallace et al. Nov 2001 B1
6328229 Duronio et al. Dec 2001 B1
6458386 Schacht et al. Oct 2002 B1
6458889 Trollsas Oct 2002 B1
6624245 Wallace et al. Sep 2003 B2
6706690 Reich et al. Mar 2004 B2
7320962 Reich et al. Jan 2008 B2
7435425 Qian et al. Oct 2008 B2
7547446 Qian et al. Jun 2009 B2
7871637 Qian et al. Jan 2011 B2
20020193448 Wallace et al. Dec 2002 A1
20030064109 Qian et al. Apr 2003 A1
20060147492 Hunter et al. Jul 2006 A1
20060167561 Odar et al. Jul 2006 A1
20080085316 Qian et al. Apr 2008 A1
20080091277 Deusch et al. Apr 2008 A1
20090142396 Odar et al. Jun 2009 A1
20100028309 Odar et al. Feb 2010 A1
20100292717 Petter-Puchner et al. Nov 2010 A1
20100318048 Hoeffinghoff et al. Dec 2010 A1
Foreign Referenced Citations (44)
Number Date Country
1270240 Oct 2000 CN
0282316 Sep 1988 EP
0376931 Jul 1990 EP
0132983 Dec 1991 EP
0493387 Jul 1992 EP
0891193 Jan 1999 EP
0612252 Dec 1999 EP
1084720 Mar 2001 EP
1283063 Feb 2003 EP
1484070 Dec 2004 EP
01414370 Apr 2007 EP
51-125156 Nov 1976 JP
59-113889 Jun 1984 JP
05308969 Nov 1993 JP
6-254148 Sep 1994 JP
08-024325 Jan 1996 JP
9-504719 May 1997 JP
07090241 Apr 2007 JP
10-1991-0007847 Oct 1991 KR
WO 8600912 Feb 1986 WO
WO 9221354 Dec 1992 WO
WO 9222252 Dec 1992 WO
WO 9427630 Dec 1994 WO
WO 9512371 May 1995 WO
WO 9515747 Jun 1995 WO
WO 9604025 Feb 1996 WO
WO 9606883 Mar 1996 WO
WO 9610374 Apr 1996 WO
WO 9610428 Apr 1996 WO
WO 9614368 May 1996 WO
WO 9639159 Dec 1996 WO
WO 9737694 Oct 1997 WO
WO 9808550 Mar 1998 WO
WO 9913902 Mar 1999 WO
WO 0222184 Mar 2002 WO
WO 02-070594 Sep 2002 WO
WO 03007845 Jan 2003 WO
WO 2004108179 Dec 2004 WO
WO 2006031358 Mar 2006 WO
WO 2006118460 Nov 2006 WO
WO 2007001926 Jan 2007 WO
WO 2007137839 Dec 2007 WO
WO 2007137839 Dec 2007 WO
WO 2008016983 Feb 2008 WO
Non-Patent Literature Citations (92)
Entry
Hood et al., “Efficacy of Topical Hemostat Floseal Matrix in Vascular Surgery,” 24th World Congress of the International Society for Cardiovascular Surgery (Sep. 12-16, 1999), 2 pages total.
English translation of the Official Japanese Action in JP Patent Application No. 2001-502866 mailed Dec. 28, 2009, 5 pages.
Ansell et al., “Gelfoam and Autologous Clot Embolization: Effect on Coagulation”, Invest. Radiol. (1978) 13:115-120.
Barton et al., “Fibrin Glue as a Biologic Vascular Patch—A Comparative Study” (abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from) J. Surg. Res. (1986) 40(5): 510-513.
Boyers et al., “Reduction of Postoperative Pelvic Adhesions in the Rabbit with Gore-Tex Surguical Membrane” Fert. Ster. (1988) 49(6):1066-1070.
Cantor et al., “Gelfoam and Thrombin in Gastrointestinal Bleeding: An Experimental Study”, pp. 890-893, (1950).
Cantor et al., “Gelfoam and Thrombin in Treatment of Massive Gastroduodenal Hemmorhage: A Preliminary Report” Am J. Surg. (1950) pp. 883-887.
Cantor et al., “Gelfoam and Thrombin in Treatment of Massive Upper Gastrointestinal Hemorrhage”, Am. J. Surg. (1951) pp. 230-235.
Chuang et al., “Sheath Needle for Liver Biopsy in High-Risk Patients”, Radiology (1988) 166:261-262.
Collins et al., “Enemata of Gelfoam-Milk Suspension Combined with Thrombin Solution to Control Massive Hemorrhage Following Anorectal Surgery”, Am. J. Proctol. (1951) 2:60-63.
Edgerton et al., “Vascular Hamartomas and Hemangiomos: Classification and Treatment” Southern Med. J. (1982) 75(12):1541-1547.
Heller et al., “Release of Norethindrone from Poly(Ortho Esters)” Polymer Engineering Sci. (1981) 21:727-731.
Hotz et al., “Collagen and Fibrin as Biologic Binders from Granular Hydroxyapatite” (abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from) Dtsh. Z. Mund. Kiefer Geichtshir. (1989) 13(4):296-300.
Jeong et al., “Biodegradable Block Copolymers as Injectible Drig-Delivery Systems” Nature (1997) 388:860-862.
Krill et al., “Topical Thrombin and Powdered Gelfoam: An Efficiaent Hemostatic Treatment for Surgery”, J. Tenn. Dent. Assoc. (1986) 66(2):26-27.
Langer et al., “Chemical and Physical Structure of Polymerns as Carriers for Controlled Release of Bioactive Agents: A Review” Rev. Marco Chem. Phys. (1983) C23(1):61-126.
Leong et al., “Polyanhydrides for Controlled Release of Bioactive Agents” Biomaterials (1986) 7:364-371.
Leong et al., “Polymeric Controlled Drug Delivery” Adv. Drug Delivery Rev. (1987)1:199-233.
Maok, “Hemostatic Agents” (1991) Today's O.R. Nurse, pp. 6-10.
Masar et al., “Synthesis of Polyurethanes and Investigation of their Hydrolytic Stability” J. Polymer. Sci., Polymer Symposium (1979) 66:259-268.
McClure et al., “Massive Gastroduodenal Hemorrhage: Treatment with Powdered Gelfoam and Buffered Thrombin Solution” Surg. (1952) 32:630-637.
Pitt et al., “Controlled Release of Bioactive Materials”, R. Baker, Ed., Academic Press, New York, 1980.
Riley et al., “Percutaneous Liver Biopsy with Plugging of Needle Track: A Safe Method for Use in Patients with Impaired Coagulation” Lancet (Aug. 25, 1984) pp. 436.
Sidman et al., “Biodegradable, Implantable Sustained Release Systems Based on Glutamic Acid Copolymers” J. Membrane Science (1979) 7:227-291.
Sugitachi et al., “A Newly Devised Chemo-embolic Agent, G.T. XIII-ADM.” (English abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from) Gan. To. Kagaku Ryoho. (1985) 12(10) 1942-1943.
Sugitachi et al., “Locoregional Therapy in Patients with Maignant Pleural Effusion—Two Different Kinds of BAC Therapy” (English abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from) Gan. To. Kagaku Ryoho. (1992) 19(10):1640-1643.
Sugitachi et al., “Preoperative Transcatheter Arterial Chemo-embolization for Locally Advanced Breast Cancer: Application for New Thrombotic Materials” Japan J. Surg. (1983) 13(5):456-458.
Tobin et al., “Plugged Liver Biopsy in Patients with Impaired Coagulation” Digestive Diseases and Science (1989) 34(1):13-15.
Tucker et al., “Absorbable Gelatin (Gelfoam) Sponge” Charles T. Thomas, Publisher, Springfiled, Illinois, 3-125, (1965).
Vander Salm et al., “Reduction of Sternal Infection by Application of Topical Vancomycin” J. Thorac. Surg. (1989) 98:618-622.
Yuki et al., “Effects of EndoscopicVariceal Sclerotherapy using GT XIII on Blood Coagulation Tests and the Renal Kallikrein-kinin System” (English abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from) Gastroentral. Japan (1990) 25(5):561-567.
Zins et al., “US-Guided Percutaneous Liver Biopsy with Plugging of the Needle Track: A Prospective Study in 72 High-Rish Patients” Radiology (1992) 184(3):841-843.
Bruck, S. D., Ed., Controlled Drug Delivery, CRC Press, Boca Raton, FL (1983) A title page and table of contents.
Cheung, David T., et al., “Mechanism of crosslinking of proteins by glutaraldehyde IV: In Vitro and In Vivo stability of a crosslinked collagen matrix”, Connective Tissue Research, 1990;25(1), pp. 27-34.
Jonas, Richard A., et al., “A new sealant for knitted Dacron prostheses: Minimally cross-linked gelatin”, J. Vasc. Surg., Mar. 1988;7(3), pp. 414-419.
Larson, Paul O., “Topical Hemostatic Agents for Dermatologic Surgery”, J. Dermatol. Surg. Oncol., Jun. 1988;14(6), pp. 623-632.
McPherson, J. M. et al., “An examination of the biologic response to injectable, glutaraldehyde cross-linked collagen implants”, J. Biomed. Mater. Res., Jan. 1986;20(1), pp. 93-107.
McPherson, J. M., et al., “The preparation and physiochemical characterization of an injectable form of reconstituted, glutaraldehyde cross-linked, bovine corium collagen”, J. Biomed. Mater. Res., Jan. 1986;20(1), pp. 79-92.
McPherson, John M., et al., “The Effects of Heparin on the Physiochemical Properties of Reconstituted Collagen”, Coll. Relat. Res., Jan. 1988;8(1), pp. 65-82.
Nimni, M. E., et al., “Chemically modified collagen: A natural biomaterial for tissue replacement”, J. Biomed. Mater. Res., Jun. 1987;21(6), pp. 741-771.
Nimni, Marcel E., “The cross-linking and structure modification of the collagen matrix in the design of cardiovascular prosthesis”, J. of Cardiac Surgery, Dec. 1988.;3(4), pp. 523-533.
Rosenblatt, Joel, et al., “Effect of electrostatic forces on the dynamic rheological properties of injectable collagen biomaterials”, Biomaterials, 1992;13(12), pp. 878-886.
Rosenblatt, Joel, et al., “Injectable collagen as a pH-sensitive hydrogel”, Biomaterials, Oct. 1994;15(12), pp. 985-995.
Rossler, B., et al., “Collagen microparticles: preparation and properties”, J. Microencapsulation, Jan.-Feb. 1994;12(1), pp. 49-57.
Wallace, Donald G., et al., “Injectable cross-linked collagen with improved flow properties”, J. of Biomedical Materials Research, Aug. 1989;23(8), pp. 931-945.
Wallace, Donald, “The relative contribution of electrostatic interactions to stabilization of collagen fibrils”, Biopolymers, May-Jun. 1990; 29(6-7), pp. 1015-1026.
Barrow, D.L., et al.; “The Use of Greater Omentum Vascularized Free Flaps for Neurosurgical Disorders Requiring Reconstruction”; J. Neurosurg.; vol. 60; pp. 305-311 (Feb. 1984).
Baxter product brochure for TissuFleece E, TissuCone E and TissuFoil E (2003).
Baxter Product Catalogue; Collagen; 4 pages (2006).
Chaplin, J.M., et al.; “Use of an Acellular Dermal Allograft for Dural Replacement: An Experimental Study”; Neurosurgery: vol. 45:2; pp. 320-327 (Aug. 1999).
Collins, Ronald et al., “Use of Collagen Film as a Dural Substitute: Preliminary Animal Studies”, Journal of Biomedical Materials Research, vol. 25, 267-276 (1991).
Filippi, R., et al.; “Bovine Pericardium for Duraplasty: Clinical Results in 32 Patients”; Neurosurg. Rev.; vol. 20; pp. 103-107 (2001).
GentaFleece Kollagenvlies Version 5 found on internet at: http://www.advancingbiosurgery.com/en—EU/downloads/ifu—gentafleece.pdf, Mar. 2002, 2 pages.
Hieb, Lee D. et al., “Spontaneous Postoperative Cerebrospinal Fluid Leaks Following Application of Anti-Adhesion Barrier Gel”, SPINE vol. 26, No. 7, pp. 748-751, 2001.
Kim, Kee D., et al., “Reduction in Leg Pain and Lower-Extremity Weakness with Oxiplex/SP Gel for 1 Year after Laminactomy, Laminotomy, and Disectomy”, Neurosurg Focus 17 (1): Clinical Pearl 1, Jul. 2004, pp. 1-6.
Kline, D.G.; “Dural Replacement with Resorbable Collagen”; Arch Surg; vol. 91; pp. 924-929 (Dec. 1965).
Knopp U., “A new collagen foil versus a cadaveric dura graft for dural defects—a comparative animal experimental study”, EANS—12th European Congress of Neurosurgery, Lisbon, Sep. 7-12, 2003, 663-666.
Kuhn, J. et al., “Bilateral Subdural Haemotomata and Lumbar Pseudomeningocele Due to a Chronic Leakage of Liquor Cerebrospinalis after a Lumbar Disectomy with the Application of ADCON-L Gel”, J. Neural Neurosurg. Psychiarty 2005; 76: 1031-1033.
Laquerriere, A., et al.; “Experimental Evaluation of Bilayered Human Collagen as a Dural Substitute”; J. Neurosurg; vol. 78; pp. 487-491 (Mar. 1993).
Le, Anh X. et al., “Unrecognized Durotomy After Lumbar Discectomy: A Report of Four Cases Associated with the Use of ADCON-L”, SPINE vol. 26, No. 1, pp. 115-118, 2001.
Lee, J.F., et al.; “Experimental Evaluation of Silicone-Coated Dacron and Collagen Fabric-Film Laminate as Dural Substitutes”; J. Neurosurg.; vol. 27; pp. 558-564 (Apr. 1967).
Matsumoto, K., et al.; “A Gelatin Coated Collagen-Polyglycolic Acid Composite Membrane as a Dural Substitute”; ASAIO Journal; pp. 641-645 (2001).
Maurer, P.K., et al.; “Vicryl (Polyglactin 910) Mesh as a Dural Substitute”; J Neurosurg; vol. 63; pp. 448-452 (Sep. 1985).
Meddings, N., et al.; “Collagen Vicryl—A New Dural Prosthesis”; Acta Neurochir; vol. 117; pp. 53-58 (1992).
Mello, L.R., et al.; “Duraplasty with Biosynthetic Cellulose: An Experimental Study”; J Neurosurg; vol. 86; pp. 143-150 (Jan. 1997).
Narotam, P.K., et al.; “A Clinicopathological Study of Collagen Sponge as a Dural Graft in Neurosurgery”; J Neurosurg; vol. 82; pp. 406-412 (Mar. 1995).
Narotam, P.K., et al.; “Experimental Evaluation of Collagen Sponge as a Dural Graft”; British Journal of Neurosurgery; vol. 7; pp. 635-641 (1993).
O'Neill, P., et al.; “Use ofPorcine Dermis as Dural Substitute in 72 Patients”; J. Neurosurg.; vol. 61;pp. 351-354 (Aug. 1984).
Palm, S.J., et al.; “Dural Closure with Nonpenetrating Clips Prevents Meningoneural Adhesions: An Experimental Study in Dogs”; Neurosurgery; vol. 45:4; pp. 875-882 (Oct. 1999).
Parizek, J., et al.; “Detailed Evaluation of 2959 Allogeneic and Xenogeneic Dense Connective Tissue Grafts (Fascia Lata, Pericardium, and Dura Mater) Used in the Course of20 Years for Duraplasty in Neurosurgery”; Acta Neurochir; vol. 139; pp. 827-838 (1997).
Park, Y-K., et al.; “Prevention ofArachnoiditis and Postoperative Tethering of the Spinal Cord with Gore-Tex Surgical Membrane: An Experimental Study with Rats”; Neurosurgery; vol. 42 :4; pp. 813-824 (Apr. 1998).
PCT International Preliminary Report on Patentability and Written Opinion mailed Feb. 17, 2009, International Application No. PCT/US2007/074984, 8 pages.
Pietrucha, K.; “New Collagen Implant as Dural Substitute”; Biomatarials; vol. 12; pp. 320-323 (Apr. 1991).
Porchet, Francois, “Inhibition of Epidural Fibrosis with ADCON-L: Effect on Clinical Outcome One Year Following Re-operation for Recurrent Lumbar Radiculopathy”, 1998, pp. 1-10.
Raul, J.S., et al.; “Utilisation du Polyester Urethane (Neuro-Patch®) Comme Substitut Dural”; Neurochirugie; vol. 49:2-3; pp. 83-89 (2003), English abstract only on p. 83.
Raul, J.S., et al.; “Utilisation du Polyester Urethane (Neuro-Patch®) Comme Substitut Dural”; Neurochirugie; vol. 49:2-3; pp. 83-89 (2003).
Reddy, M., et al.; “A Clinical Study of a Fibrinogen-Based Collagen Fleece for Dural Repair in Neurosurgery”; Acta Neurochir; vol. 144; pp. 265-269 (2002).
Ross, Jeffrey S. et al., “Association Between Peridural Scar and Recurrent Radicular PAIN After Lumbar Discectomy: Magnetic Resonance Evaluation”, Neurosurgery, pp. 855-863, 1996.
San-Galli, F., et al.; “Experimental Evaluation of a Collagen-Coated Vicryl Mesh as a Dural Substitute”; Neurosurgery: vol. 30:3; pp. 396-401 (1992).
Shaffrey, C.I., et al.; “Neurosurgical Applications of Fibrin Glue: Augmentation ofDural Closure in 134 Patients”; Neurosurgery; vol. 26:2; pp. 207-210 (1990).
Smith, KA, et al.; “Delayed Postoperative Tethering of the Cervical Spinal Corei”; J Neurosurg; vol. 81; pp. 196-201 (Aug. 1994).
Springorum, H.W.; “Die Verwendung von Kollagenfolien zur Uberbruckung von Defekten des Gleitgewebes bei Achillotenotomien und Achillessehnenrupturen”; Akt. Traumata!.; vol. 15; pp. 120-121 (1985), English abstract only on p. 120.
Springorum, H.W.; “Die Verwendung von Kollagenfolien zur Uberbruckung von Defekten des Gleitgewebes bei Achillotenotomien und Achillessehnenrupturen”; Akt. Traumata!.; vol. 15; pp. 120-121 (1985).
Stricker, A., et al.; “Die Verwendung von TissuFoil Membran bei der Sinusbodenaugmentation”; Ellipse; vol. 17:1; pp. 1-5 (2001), English abstract only on p. 1.
Stricker, A., et al.; “Die Verwendung von TissuFoil Membran bei der Sinusbodenaugmentation”; Ellipse; vol. 17:1; pp. 1-5 (2001).
T. Kofidis et al., “Clinically established Hemostatis Scaffold (Tissue Fleece) as Biomatrix in Tissue- and organ-engineering research”, Tissue Eng vol. 9, No. 3, 2003, S.517-523; ISSN: 1076-3279.
TissuFleece E found on internet at: http://www.biosurgery.de/Produkte/pdf/TissuFleece-E—GI.pdf, Feb. 2003, 2 pages.
Vinas, F.E., et al.; “Evaluation of Expanded Polytetrafluoroethylene (ePTFE) versus Polydioxanone (PDS) for the Repair ofDura Mater Defects”; Neurological Research; vol. 21; pp. 262-268 (Apr. 1999).
Warren, W.L., et al.; Dural Repair Using Acellular Human Dermis: Experience with 200 Cases: Technique Assessment; Neurosurgery; vol. 46:6; pp. 1391-1396 (Jun. 2000).
Ziegelaar, B.W.; “Tissue Engineering of a Tracheal Equivalent”, Doctoral Thesis at Ludwig Maximilians University, Munich, Germany; 25 pages (2004).
Ziegelaar, BW et al., “The characterisation of human respiratory epithelial cells cultured on reabsorbable scaffolds: first steps towards a tissue engineered tracheal replacement”, Biomaterials 23 (200), 1425-1438; ISSN 0142-9612.
Gibble, et al., “Fibrin glue: the perfect operative sealant?” Reviews, Transfusion, 1990, pp. 741-747, vol. 30 No. 8.
Related Publications (1)
Number Date Country
20080286376 A1 Nov 2008 US
Continuations (1)
Number Date Country
Parent 09908464 Jul 2001 US
Child 12176945 US